step 2 semaglutide 2·4 mg once a week in adults with overweight or obesity, and type diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Two Years on Semaglutide -

According to FDA prescribing information, these include: Nausea (occurring in 1544% of patients depending on formulation and dose) Vomiting (524% of patients) Diarrhea (830% of patients) Abdominal pain (511% of patients) Constipation (324% of patients) These gastrointestinal symptoms typically emerge during dose escalation and often diminish over time as physiological tolerance develops

Always discuss these factors during follow-ups to avoid underdosingor overdosingaccidentally

Comparing those who received Pilot services to Medicaid enrollees who screened positive for social risks but lived in regions not covered by the Pilots, the interim evaluation found: Spending (including both Pilot service spending and spending for medical care) was, on average, $85 less per Pilot participant per month

Obesity can lead to metabolic syndrome, which is a cluster of health issues that can lead to cardiovascular (heart) disease

For people using semaglutide to manage weight loss, understanding how this medication might interact with aspirin is essential

Support health goals, like weight loss